(FGEN) FibroGen - Ratings and Ratios

FibroGen, Inc. is a biopharmaceutical company focused on developing innovative therapies for severe unmet medical conditions. The companys pipeline includes Pamrevlumab, a monoclonal antibody targeting connective tissue growth factor (CTGF), currently in Phase III trials for locally advanced pancreatic cancer. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has completed Phase III trials for anemia in chronic kidney disease (CKD) in multiple regions, including China, Europe, and Japan, and is also in Phase III development for anemia associated with myelodysplastic syndromes (MDS). FibroGen has established collaborations with major pharmaceutical companies, including Astellas Pharma and AstraZeneca, to advance its pipeline and expand market reach. Incorporated in 1993 and headquartered in San Francisco, California, the company has built a reputation for its innovative approach to addressing complex medical challenges.

Ticker Symbol: FGEN Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Average Volume 20d: 7957734 Last Price: 0.39 SMA 20: 0.50 SMA 50: 0.52 SMA 200: 0.59 ATR: 0.07 Market Cap: 40.64M USD P/E: 0.00 P/E Forward: 61.35 P/B: 53.83 P/S: 0.23 RoE: 60.38 3-Month Forecast: Based on and , FibroGens stock is expected to face downward pressure in the near term due to its current price trading below key moving averages (SMA 20, SMA 50, and SMA 200). The average true range (ATR) of 0.07 indicates moderate volatility, suggesting potential price fluctuations within a narrow range. However, the companys forward P/E of 61.35 reflects investor confidence in its long-term growth prospects, particularly tied to the success of Roxadustat in global markets and the progression of Pamrevlumab through late-stage trials. Over the next three months, the stock may experience increased trading activity due to its relatively high average volume of 7.96 million shares. The market capitalization of $40.64 million and price-to-book ratio of 53.83 highlight the markets valuation of the companys intangible assets and pipeline potential. The companys return on equity (RoE) of 60.38% underscores its ability to generate profits from shareholder equity. Overall, the stocks performance will likely hinge on clinical trial outcomes and regulatory approvals, making it a high-risk, high-reward investment in the biotechnology sector.